Transcriptomics

Dataset Information

298

Charaterization of genetic alterations and gene expression signatures found in BCR-ABL inhibitor-resistant KCL-22 subpopulations and single clones


ABSTRACT: KCL-22 is a chronic myeloid leukemia (CML) cell line derived from a patient in blast crisis phase and harbors the BCR-ABL translocation. The catalytic (ATP-competitive) BCR-ABL inhibitors imatinib and nilotinib have dramatically improved CML patient outcome, but the development of resistance remains a clinical challenge. The recent identification of allosteric BCR-ABL inhibitors, such as GNF-2, which target the enzyme by binding to the myristoyl pocket rather than catalytic site of ABL1, may provide a strategy to broadly overcome resistance to the class of ABL1 ATP competitive inhibitors. We therefore wanted to use the ClonTracer barcoding system to compare the clonal responses of KCL-22 to imatinib, nilotinib and GNF-2. RNA-seq was employed to characterize genetic alterations and gene expression signatures in the pooled cell populations resistant to BCR-ABL inhibitors as well as single clones showing differential response to the three inhibitors. mRNA profiling of the subpopulations and single clones of human CML cell line KCL-22 that contribute to BCR-ABL inhibitor resistance

ORGANISM(S): Homo sapiens  

SUBMITTER: Daniel Rakiec   Joshua M Korn  David A Ruddy  Hyo-eun C Bhang  Frank Stegmeier 

PROVIDER: E-GEOD-62121 | ArrayExpress | 2014-10-07

SECONDARY ACCESSION(S): SRP048701GSE62121PRJNA263248

REPOSITORIES: GEO, ArrayExpress, ENA

Similar Datasets

2009-12-19 | GSE19567 | GEO
2010-01-19 | E-GEOD-19567 | ArrayExpress
2010-10-10 | GSE24493 | GEO
2007-02-24 | GSE7114 | GEO
| GSE103908 | GEO
2010-07-15 | GSE21499 | GEO
2010-07-15 | E-GEOD-21499 | ArrayExpress
2009-04-25 | E-GEOD-7114 | ArrayExpress
| GSE60315 | GEO
| GSE99656 | GEO